Tempest Therapeutics, Inc. (TPST): Submission of Matters to a Vote of Security Holders
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001544227 0001544227 2026-06-18 2026-06-18 0001544227 us-gaap:CommonStockMember 2026-06-18 2026-06-18 0001544227 us-gaap:SeriesAPreferredStockMember 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pu
How this was made
The 30-second read
Why it matters
The key new information is that shareholders approved Nasdaq Rule 5635 issuances of common stock related to outstanding warrants (Series A/B and common warrants), which can lead to future common stock issuance upon warrant exercise.
Market read
This is a procedural but tradable corporate action: approval of warrant-linked issuances can affect dilution expectations, though the filing lacks proceeds/timing details.
What to watch
The filing does not state exercise price, expected timing, or net proceeds; actual dilution depends on whether/when warrants are exercised.
Background
The company filed an SEC 8-K reporting final results from its June 18, 2026 special stockholder meeting (Item 5.07).
Ticker impact
Tempest Therapeutics’ stockholders approved Nasdaq Rule 5635 issuances tied to Series A/B and common warrants, enabling potential future dilution.
Likely modest, dilution-overhang effect; direction depends on whether the market views the warrant exercises as financing-positive versus dilutive.
The filing reports final voting results approving warrant-linked issuances, but provides no pricing, proceeds, or exercise timing—so impact is mainly about dilution risk rather than a fresh capital raise.
Market effects
Limited read-across to biotech financing norms; this is company-specific warrant approval rather than a sector-wide regulatory change.
None.
None.
Counterpoint
Approval may be viewed as removing a procedural hurdle, reducing uncertainty and potentially supporting financing plans if exercises follow.
Key entities
- companyTempest Therapeutics, Inc.
Nasdaq-listed biotech whose shareholders approved warrant-linked common stock issuances under Nasdaq Rule 5635.
- regulationNasdaq Rule 5635
Nasdaq shareholder approval requirement for certain issuances; approval enables the company’s planned warrant-related share issuances.
